Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SRC | P12931 | 6/20 | 0.52 |
| ▸ | CDK2 | P24941 | 2/20 | 0.50 |
| ▸ | KDR | P35968 | 4/20 | 0.48 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.47 |
| ▸ | FCER2 | P06734 | 1/20 | 0.47 |
| ▸ | SYK | P43405 | 1/20 | 0.47 |
| ▸ | NTRK3 | Q16288 | 1/20 | 0.47 |
| ▸ | NTRK2 | Q16620 | 1/20 | 0.47 |
| ▸ | LCK | P06239 | 3/20 | 0.44 |
| ▸ | FYN | P06241 | 3/20 | 0.44 |
| ▸ | YES1 | P07947 | 3/20 | 0.44 |
| ▸ | FGFR1 | P11362 | 3/20 | 0.44 |
| ▸ | PDGFRB | P09619 | 2/20 | 0.44 |
| ▸ | APP | P05067 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | AURKA | O14965 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12848113 | 1.00 | SRC (0.52) | SRCCDK2KDRNTRK1FCER2 | |
| SCHEMBL6531975 | 1.00 | SRC (0.52) | SRCCDK2KDRNTRK1FCER2 | |
| SCHEMBL5181493 | 0.81 | CDK2 (0.52) | SRCCDK2KDRNTRK1FCER2 | |
| SCHEMBL6525150 | 0.81 | PDPK1 (0.60) | APPMAPT | |
| SCHEMBL6525147 | 0.81 | PDPK1 (0.60) | APPMAPT | |
| SCHEMBL5430411 | 0.81 | CDK2 (0.52) | SRCCDK2KDRNTRK1FCER2 | |
| SCHEMBL7136883 | 0.81 | SRC (0.58) | SRCCDK2KDRNTRK1FCER2 | |
| SCHEMBL6531199 | 0.81 | MEN1 (0.52) | PDGFRBAPPMAPT | |
| SCHEMBL6531204 | 0.81 | MEN1 (0.52) | PDGFRBAPPMAPT | |
| SCHEMBL12848343 | 0.81 | MEN1 (0.52) | PDGFRBAPPMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8765748-B2 | Indazolyl, benzimidazolyl, benzotriazolyl substituted indolinone derivatives as kinase inhibitors useful in the treatment of cancer | UNIVERSITY HEALTH NETWORK (CA) | 2014-07-01 | — | — | US | disclosed |
| US-20110065702-A1 | INDAZOLYL, BENZIMIDAZOLYL, BENZOTRIAZOLYL SUBSTITUTED INDOLINONE DERIVATIVES AS KINASE INHIBITORS USEFUL IN THE TREATMENT OF CANCER | UNIVERSITY HEALTH NETWORK | 2011-03-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110065702-A1 | INDAZOLYL, BENZIMIDAZOLYL, BENZOTRIAZOLYL SUBSTITUTED INDOLINONE DERIVATIVES AS KINASE INHIBITORS USEFUL IN THE TREATMENT OF CANCER | TNNI3K, ABL1, TK1 | SRC 9/4885CDK2 323/4885KDR 679/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.